RYTHROPOIETIN (epo) is a humoral regulator of E
The gene encoding human epo has been cloned and sequenced? and recombinant epo has been used successfully as an alternative to erythrocyte transfusions in patients with hyporegenerative anemia secondary to defective epo produ~tion. ' .~ suggest that high concentrations of epo might divert multipotent progenitors into erythroid maturation at the expense of granulocyte production. Based on those experiments it was suggested that diminished neutrophil production might be an unwanted side effect of epo administration.'." In practice, however, neither neutropenia'" nor diminished neutrophil production' have been observed.
We reported that hematopoietic progenitors obtained from fetal subjects are more susceptible to epo-induced down-modulation of neutrophil production in vitro than are progenitors from ad~lts.'~,' ' We also observed that human neonates with high serum epo concentrations (accompanying Rh hemolytic diseaseI6 and placental insuffi~iency'~"~) usually have a hyporegenerative neutropenia during their first days of life. In addition, Halperin et all9 reported neutropenia in all of seven human neonates treated with recombinant epo, although it was not clear whether the neutropenia was due to diminished neutrophil production, or indeed whether it was the result of epo administration. Therefore, although a number of observations suggest that epo administration to neonates might result in diminished neutrophil production, no direct evidence has been presented.
The present experiments tested the effect of epo administration to newborn rats on neutrophil production. Initial studies were performed to select a dose of epo that resulted in serum concentrations comparable with the in vitro concentrations required to result in down-modulation of neutrophil production. Then, beginning on the first day of life, littermates were injected with either 1,000 U epo/kg body weight or the same volume of a (vehicle) control. After three daily injections the pups were killed, their femoral and splenic marrow neutrophil reserves and heAnimal experimentsg.'" and in vitro hematocrits (P < .OOl), reticulocyte counts (P < .001), normoblasts/femur (P < .05), and normoblasts/spleen (P < .OOl).
Recipients of epo also had more erythroid colony-forming units (CFU-E) (P < .001) and higher CFU-E tritiated thymidine suicide rates (P <.01) than did controls. However, femurs and spleens of epo recipients contained fewer postmitotic neutrophils (femur, P <.01; spleen, P < .01), proliferative neutrophils (femur, P < .01; spleen, P < .02), granulocytemacrophage colony-forming units (CFU-GM) (P < .005), and lower CFU-GM tritiated thymidine suicide rates (P < .01).
Seven and nine days after twice-daily administration of 2,000 U epo/kg, blood neutrophil concentrations had diminished (P <.05). Thus, administration of high doses of recombinant epo to newborn rats resulted in diminished neutrophil production accompanying accelerated erythropoiesis. Q 1991 by The American Society of Hematology. matopoietic progenitors were quantified, and cell-cycle characteristics of progenitors were assessed.
MATERIALS AND METHODS

Animals. Sprague-Dawley rats with timed pregnancies (Charles
River Laboratories, Stone Ridge, NY) were housed at the University of Utah Vivarium. On the day of delivery, litters were culled to 8 to 10 pups per mother and the pups were administered intraperitoneal injections of either recombinant epo or an equivalent volume of the vehicle in which the epo was suspended (sterile phosphate-buffered saline with 0.02% human serum albumin). The epo (gift of Chugai-Upjohn Inc, Rosemont, IL) had a specific activity greater than 3 x Id Ulmg and a purity of greater than 99.7% by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Preceding all injections, the site was swabbed with 70% alcohol.
In the first studies, groups of three to five newborn rats were injected intraperitoneally with 20, 200, or 2,000 U epokg body weight. After 2, 8, 24, or 48 hours, blood was drawn from their external jugular veins for quantification of epo serum concentrations, and the animals were killed by decapitation. In the second studies, one day after three daily injections of 1,ooO U epokg body weight (or control) to groups of 5 to 10 newborn rats, blood was drawn by severing the jugular vein, after which the animals were killed and the spleen and femurs removed. In the third studies, groups of four to five newborn rats received twice daily intraperitoneal injections of 2,000 U epokg body weight (or control). After 5, 
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7, or 9 days of injections, blood was obtained as described previously and the animals were killed. Quantification of serum epo concentrations, and erythroid and granulocytic cells in the blood, marrow, and spleen. Serum epo concentrations were quantified by enzyme immunoassay (EIA) (Amgen Biologicals, Thousand Oaks, CA). Hematocrits were determined by centrifugation of heparinized microcapillary tubes (DamonDEC Division, Needham Heights, MA). Reticulocyte counts were performed on films of blood incubated with methylene blue. Circulating concentrations of nucleated blood cells were determined electronically (Coulter Electronics, Hialeah, FL). Blood smears were stained with Wright stain and subjected to 300 to 500 cell differential counts. . . .
-SCM used were those previously determined to be plateau concent r a t i o n~.~~ Tritiated thymidine suicide studies were performed as described by Lu et aLu Briefly, aliquots of cells were incubated with either a MEM alone, a MEM containing "cold" (nonradioactive) thymidine, a MEM containing tritiated thymidine of high specific activity (80 Ci/ mmol/L; New England Nuclear, North Billerca, MA), or with a MEM containing tritiated thymidine plus excess "cold" thymidine.
After a 20-minute incubation, with agitation every 5 minutes, cells were washed twice and placed into clonogenic cultures as described previously.
Data analysis. Statistical comparisons were performed using the Student t-test, the paired t-test, or the Mann-Whitney U-test, as applicable.
Cell-cycle analysis of hematopoietic progenitors.
RESULTS
Serum epo concentrations.
Serum concentrations of epo before and after administration of 20, 200, and 2,000 U epokg body weight are shown in Table 1 . Eight hours after administration of 2,000 Ukg, epo concentrations were 2,012 2 155 mU/mL (mean 2 SEM). A dose of 1,000 U/kg was selected for the subsequent series of studies, based on our previous observation that a concentration of 1,000 mU/mL was sufficient to reduce neutrophil production .~ mean f SEM) than did control recipients (803 f 74 x lo3/ femur, P < .Ol). Recipients of epo also had fewer proliferative neutrophils (231 f 17 X 103/femur) than controls (377 f 37 x 103/femur, P <.01). However, epo recipients had more normoblasts (2,462 2 280 x 103/femur) than controls (1,894 f 248 x 103/femur, P <.OS). No differences were observed in the number of macrophages or lymphocytes flushed from femurs of epo versus control recipients.
The spleens of epo recipients contained fewer postmitotic neutrophils (1,821 f 239 X 103/spleen) than did spleens of control recipients (4,560 f 690 x lo3, P < .01). Spleens of epo recipients also contained fewer proliferative neutrophils (4,620 f 990 X 103/spleen) t h a n controls 
005).
To determine the effect of epo administration on the concentration of hematopoietic progenitors in the circulating blood, clonogenic cultures were performed on lightdensity blood cells from epo and control recipients. Circulating concentrations of BFU-E were higher in epo recipients (203 f 87/106 plated light-density blood cells, mean f SEM) than in control recipients (5 f 2/106, P <.OS). No differences were noted, however, in circulating concentrations of CFU-GM (135 +. 49/106 in epo recipients v 123 f 25/106 in control recipients) or CFU-MIX (43 f 13/106 in epo recipients v 15 f 2/106 in control recipients, P = .08).
Effect of epo administration on cell cycle status of hematopoieticprogenitors. The effect of epo injections on susceptibility of hematopoietic progenitors to tritiated thymidine of high specific activity is shown in Tables 2 and 3. Fewer BFU-E colonies were observed (Table 2, upper panel) after incubation with tritiated thymidine than after incubation with media alone, or after incubation with "cold" thymidine, or after incubation with the combination of tritiated thymidine plus excess "cold" thymidine. The effect of epo injections on cycling status of CFU-GM is shown in the lower panel of Table 2 . Fewer CFU-GM colonies were observed after incubation with tritiated thymidine than after incubation with media alone, or after incubation with "cold" thymidine, or with the combination of tritiated thymidine plus a great excess of "cold" thymidine. In addition, similar to the experiment shown in Fig 3, epo administration resulted in the growth of fewer CFU-GM colonies. No effect was observed on CFU-MIX colonies.
The tritiated thymidine suicide rates of CFU-E, BFU-E, CFU-GM, and CFU-MIX after 3 days of epo or control injections are shown in Table 3 . Injections of epo resulted in a higher percentage of CFU-E killed by incubation with Before culturing, the spleen cells were incubated in either media alone, or media plus nonradiolabeled ("cold") thymidine, tritiated thymidine of *P < .05 v"hot" thymidine. tP < .05 v epo recipients. high specific activity ("hot"), or the combination of "cold" plus "hot" thymidine. tritiated thymidine. However, administration of epo resulted in a lower percentage of CFU-GM killed by incubation with tritiated thymidine. No significant effect of epo administration was observed on the tritiated thymidine suicide rates of BFU-E or CFU-MIX.
Effect of twice-daily injections of 2,000 U epolkg body weight on circulating normoblast and neutrophil concentrations. These studies were performed to determine whether injecting newborn rats with even higher doses of epo would result in a diminution in blood neutrophil concentration. After 9 days of twice-daily injections of 2,000 U epokg body weight (or control), no difference was observed in body weight of the animals (epo recipients, 20 f 1 g; control recipients, 20 f 1 g, mean rf: SEM). Hematocrits were higher in epo recipients (0. suggest that if erythropoiesis is accelerated sufficiently, neutrophil production will decrease. Despite these suggestions, no direct evidence of reduced neutrophil production has been presented after the administration of high doses of recombinant epo to animals or humans.
We hypothesized that if recombinant epo administration is capable of resulting in reduced neutrophil production in vivo, it might do so only under very limited conditions, such as following administration of very high doses to neonatal subjects. Our reasoning was based, in part, on the observa- tions that progenitors from neonates are more sensitive to down-modulation of neutrophil production by epo in v i t r~, '~,~ and their pool sizes of multipotent progenitors are considerably smaller, per gram of body weight, than those of adults.26 In a previous study, epo injections in 2-week-old rats did not result in reduced neutrophil producti~n.'~ However, in the present study, using rats on the first day of life, we observed evidence of decreased neutrophil production.
The evidence for diminished neutrophil production in these animals included: (1) reduction in the absolute number of postmitotic neutrophils in femurs and spleens; (2) reduction in the absolute number of proliferative neutrophils in femurs and spleens; (3) reduction in concentrations of CFU-GM; (4) reduction in CFU-GM tritiated thymidine suicide rate; and (5) decreased concentrations of circulating neutrophils after 7 and 9 days of epo injections.
The present studies do not clarify whether the epo administration resulted in a transient downregulation of neutrophil production, or a reduction that would continue as long as the epo was administered. Also, the studies do not clarify the mechanism by which epo resulted in diminished neutrophil production. However, previous studies suggest several possibilities. One, originally referred to by Van Zant and Goldwasser as "stem-cell ~ompetition,""~'~ involves diversion of multipotent progenitors into erythroid production and, thus, away from granulocytopoiesis. A second possibility is that epo acts, directly or indirectly, to reduce clonal maturation of CFU-GM.I3 Indeed, this effect has been demonstrated with human fetal CFU-GM in vit~0.I~ Studies by Chen et al,27 Nicola et al,28329 and Walker et aI3O suggest that, although none of the hematopoietic growth factors directly compete for the same variety of receptor, the binding of certain growth factors can downmodulate the availability of receptors for others. Therefore, if fetal CFU-GM express epo receptors, perhaps the binding of epo to those receptors results in downmodulation of receptors for neutrophilic growth factors. A third possibility is that high concentrations of epo result in reduced elaboration, or activity, of granulocytopoietic growth factors. No evidence has been presented in support of this latter hypothesis.
Administration of recombinant epo to certain anemic neonates has been suggested as a potentially attractive alternative to erythrocyte transfu~ion.'~*~'.~~ In view of the already reduced antibacterial defense capability of neon a t e~?~ we suggest additional investigations into the effect of epo on neutrophil production before its widespread implementation as a treatment for anemic neonates.
